Common corruption of the mTOR signaling network in human tumors. - Wikidata - awgldk - TriplyDB

Common corruption of the mTOR signaling network in human tumors.

Common corruption of the mTOR signaling network in human tumors.

http://www.wikidata.org/entity/Q37643431

about

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1 Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?Amino acid management in cancer Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells mTORC1 signaling activates NRF1 to increase cellular proteasome levels HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression The expanding role of mTOR in cancer cell growth and proliferation Architecture of human mTOR complex 1 Where is mTOR and what is it doing there?Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4 Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR Activation of a metabolic gene regulatory network downstream of mTOR complex 1 Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer.Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.Identification of rs7350481 at chromosome 11q23.3 as a novel susceptibility locus for metabolic syndrome in Japanese individuals by an exome-wide association study.mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.Regulation of mTORC1 signaling by pH Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion.SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis.MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma Role of Notch and its oncogenic signaling crosstalk in breast cancer.Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling.mTOR signaling in epilepsy: insights from malformations of cortical development Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.Glutaminolysis and autophagy in cancer New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

P2860

Q24293153-6F24F88F-2AC5-4C67-873A-50FAA631442D Q24628724-8DCB9E47-F493-4827-A589-65FAF911726E Q26784413-8546464C-7AAB-44CB-B0D4-160F2EF9836D Q26798087-C92A8D0D-4A87-4648-912B-3495650FF938 Q26830194-16135036-5D21-4FC5-9564-0118A2A760F9 Q26861403-E004F0E9-B4AC-4E47-8C4A-20E71AE9CC52 Q27012468-C43B3CBA-F1DC-4EFA-B5C9-21CB82176777 Q27025886-A251B4C7-922A-4A79-9A76-900263E7D8BE Q27027797-7C751BD3-00AB-417B-8A65-6E8EDACB9E4F Q27703146-01235963-2ED8-41A0-8FA0-36A167CBB4CF Q28305068-E1747B67-9CDB-4ACF-BE17-03DE8BB393C0 Q28307704-E9FFEAC5-B08D-46D0-8F23-EB36302DA88F Q28508613-96D6B749-02FF-4D43-8BED-64667C1C31F5 Q28550149-0AF2A375-811A-4208-9749-4EEE67749B89 Q28550394-05CE2CC9-029C-4CB8-8C61-141F423405DC Q29037521-FF459B0B-6D62-4FB0-8339-6ABD5A305AF3 Q29615179-01DB9955-97E5-4610-996D-643A79917E15 Q30541218-A968E002-C744-472A-ADA7-B64165CC9192 Q33790320-1A291C02-997D-4551-817A-7044214132F3 Q33851000-CBD70FDE-E56F-45C7-AD61-035C7707D571 Q33889172-4DBE1379-C0EC-41D3-B983-1A12894FA63E Q33919744-A93A1370-C1C9-43DD-8ECF-72458479538D Q33955047-29A762D8-5BF0-427A-BC94-D5427A663665 Q33955139-24641FFA-FD53-49BB-A9DF-2BDB4F0EF049 Q34094993-3653466D-87A1-41F2-AAB2-D644DE70C720 Q34177843-C1260BCB-16E6-4938-9840-C62C8F912F8E Q34202686-4DB5BBB6-DD5C-4B76-A19B-FF99EEBB5FCF Q34257789-6C9E50AF-69A1-4E33-ABE1-A647051165B3 Q34373638-6F83EAF5-EDA6-436D-BDB3-205B8CE59229 Q34485641-65AC6D76-8B0E-46C1-BC89-BF51A58B8778 Q34697373-B3FBF0F3-167B-415F-A59B-157CB1545B60 Q34926558-2CFCABDC-B5EC-4B17-BADB-F59F22C3D8B1 Q34959225-D0486EFC-10A2-478D-8E90-61DDE6D72188 Q35245211-7F9419A6-4F32-4C59-B170-049672969E61 Q35550185-086BEBC0-524B-4108-927D-E87B834DA516 Q35634079-3D35FF47-9F7F-4F8B-B3F4-BE25A0569336 Q36062128-9F0B830E-73B4-434A-813A-26EFAA4F281B Q36095183-26A08943-D113-4B7D-95D2-E03CCC141C9E Q36111779-A94AB932-97CD-4A89-BFB0-102EBDB94F57 Q36144084-2924917F-1B21-4C87-A878-D1A8E7CA5287

P2860

Common corruption of the mTOR signaling network in human tumors.

http://www.wikidata.org/entity/Q37643431

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Common corruption of the mTOR signaling network in human tumors.

@en

Common corruption of the mTOR signaling network in human tumors.

@nl

type

label

Common corruption of the mTOR signaling network in human tumors.

@en

Common corruption of the mTOR signaling network in human tumors.

@nl

prefLabel

Common corruption of the mTOR signaling network in human tumors.

@en

Common corruption of the mTOR signaling network in human tumors.

@nl

P1433

Q37643431-46430F10-F421-493F-BB37-937B5C50064D

P1476

Q37643431-D58901B8-AF05-40FA-B982-1A3C12E66E31

P2093

Q37643431-BBE8A03C-62BC-4117-A7C6-3116B805F80C

Q37643431-D8765A79-2EB7-4B9F-9DDB-C93045102893

P2860

Q37643431-080B1504-CF75-4847-B589-1BFD48CB1228

Q37643431-0B5CEE29-693E-447A-BB89-36ADE864D231

Q37643431-0B99F650-2DB8-4FA7-AC05-E1215F2F06E5

Q37643431-0BDED19D-432B-48B1-8D9E-8284D6241DF5

Q37643431-13522D94-A7A8-45BE-B42B-795514B92EF0

Q37643431-1459FAAE-3AB3-45D1-B5E3-F55D743DEA4E

Q37643431-173AF2A5-FAA9-4CEC-9ACB-E859E0B199A2

Q37643431-17638569-81E3-46C2-B02A-A73DF5313050

Q37643431-1911FD2B-2154-4BE9-A896-AF5ED8ECAD48

Q37643431-1B91DD18-FE4B-43CB-B968-56A581E5FB6C

P2888

Q37643431-6BD9AA06-960E-418E-87E9-484B979BB451

P304

Q37643431-A163F52C-26FD-47B3-AECD-3EEB7574257D

P31

Q37643431-7884CE8D-AD39-4B6F-B008-9B932642996D

P356

Q37643431-D2E75713-4700-4670-887B-0EDE807E7DA6

P407

Q37643431-DAA9F6E9-CA08-472D-983F-55EFBFB323E5

P478

Q37643431-C2ED81AC-2F45-411B-89AE-F3B2F45FD6E6

P577

Q37643431-9D03750E-86FD-4CA6-8FE1-32AE5DD57186

P5875

Q37643431-39E7ED31-E21A-4677-A43A-F324D0C1A6A3

P698

Q37643431-77A2B6FB-CD93-477A-A913-1531FC6ABCFA

P932

Q37643431-A4308359-9217-4935-9A29-095FF731C0F4

P356

P1433

P1476

Common corruption of the mTOR signaling network in human tumors.

@en

P2093

B D Manning

http://www.w3.org/2001/XMLSchema#string

S Menon

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

The Hallmarks of Cancer

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

P2888

P304

S43-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2009.352

http://www.w3.org/2001/XMLSchema#string

P407

P478

27 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51440348

http://www.w3.org/2001/XMLSchema#string

P698

19956179

http://www.w3.org/2001/XMLSchema#string

P932

3752670

http://www.w3.org/2001/XMLSchema#string